The domestic in vitro diagnostic (IVD) leader in the post-epidemic era is targeting India, which is growing as fast as the Chinese market. The upstream leader of China's life sciences and the world's leading in vitro diagnostic upstream platform company Fapon Biotech has been deployed in the Indian market for nearly 15 years, and the in vitro testing raw materials have more than half of the local market share.

Li Hua, International Region Director of Fapon Biotech, said: "At present, the competition in the Indian market is still relatively fierce, and it requires excellent product quality to win the competition." Comprehensive services have taken root in the Indian market, and the company's strategy is to form cooperation with most local IVD manufacturers in India. "For companies with relatively high technology dependence, in addition to regular visits to provide professional technical support, we will also provide professional technical support according to the actual situation of customers and technology transfer services.”

According to its disclosed prospectus, from 2019 to 2021, Fapon Biotech’s overseas income was 78.28 million CNY, 413 million CNY, and 803 million CNY, accounting for 27%, 39%, and 35% of its total operating income, respectively.

According to Li Hua, Fapon Biotech 's business in India covers more than 60 IVD companies, and the top 5 local manufacturers are all customers of Fapon. In 2021, Fapon will have more than half of the market share in India.